Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

iEnvision

Otsuka rewards digital health startup NeuroFlow

Mental illness tech platform wins the pharma firm's US pitch challenge

- PMLiVE

NCCN bolsters its Oncology Research Programme

Uses iEnvision to manage the programme’s projects

- PMLiVE

Lundbeck and Otsuka start phase III for Rexulti in bipolar

Drug is also in phase II trial to treat PTSD patients

- PMLiVE

Lundbeck trial failure dashes hopes in Alzheimer’s once again

Phase III trial fails to substantially improve cognition despite promising phase II data

Otsuka joins forces with IBM for Watson-based digital venture

Otsuka Digital Health will develop software to analyse psychiatric patient data

- PMLiVE

Otsuka joins its Japanese peers on Twitter

The firm's US operations make their social media debut

- PMLiVE

Envision Pharma Group expands with new Cheshire office

Appoints Anne Clare Wadsworth to lead its North West branch

FDA knocks-back Otsuka’s digital pill plans

Wants more data on its combination of Abilify and Proteus sensor and pill

- PMLiVE

Study shows Otsuka’s TB drug works even in worst cases

Deltybaeffective even in cases that are unlikely to respond to any other drug

- PMLiVE

Lundbeck and Otsuka’s Rexulti set for August launch in US

Follows the antipsychotic drug's FDA approval on Friday

- PMLiVE

Ten new medicines recommended in Europe

Includes double approvals for rare disease specialist Alexion and Novartis

- PMLiVE

Otsuka expands CNS presence with Avanir purchase

Deal for US biotech is valued at $3.5bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links